Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesCan immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionVaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protectionA new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic targetDecreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccinationPre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humansAdenoviruses in lymphocytes of the human gastro-intestinal tractImmune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Adenoviral vectors as novel vaccines for influenza.Human immunodeficiency virus vaccine trialsRecall T cell responses to bluetongue virus produce a narrowing of the T cell repertoireThe influence of delivery vectors on HIV vaccine efficacyMucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid.Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individualsRecombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyNovel adenovirus vector-based vaccines for HIV-1.Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineCD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.Fragmentation of SIV-gag vaccine induces broader T cell responses.Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Canine recombinant adenovirus vector induces an immunogenicity-related gene expression profile in skin-migrated CD11b⁺ -type DCs.Novel vaccine vectors for HIV-1.IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses.Lessons drawn from recent HIV vaccine efficacy trials.Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaquesOptimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step studyCircumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.
P2860
Q22241377-29EE3507-FA95-476C-A176-CFFBF79463E6Q26865388-95650A47-3870-4D8D-95AF-9899EC5EE1A5Q27001897-3F64184E-4F39-4DEF-9D7D-49C690EA0761Q27332360-9C18B284-54A3-4DC1-9ABE-FED73F34AE73Q27333475-E107614F-9298-4890-8959-55A2140B4EA0Q28730757-E923CE8B-E498-4C59-BC11-A71A40A3DEDBQ28741103-2BB5481C-1BA4-4F0F-8F2F-71DA171C696AQ28744382-8F668A63-7A92-4B03-A62F-E114F4CA835AQ30362489-A27764FE-7472-4D04-993D-ED42F2FB5912Q30370445-2DB8A077-ED8E-44FC-8E2C-B941B00ED6ECQ30424366-EAFD77C8-A351-4403-B5CF-4C47CBED1C56Q32178442-2D31443A-7F9C-47C6-9C62-BB26A37B5A1DQ34077543-DE0F577A-8CF5-41E5-B6C5-273CD50B9479Q34120780-2ACDF0BB-65E0-4F8C-A5DF-1F609F68A425Q34217360-968E9438-3187-449F-8A3F-221003960F9BQ34218500-2B1E0F41-8EDD-4B20-BB35-0C2966960AA7Q34240204-36DAB103-5C76-405F-84A5-EEBDF799B178Q34257640-F0445824-D222-4F3F-AC6B-21C032A4D167Q34289005-67783D71-512E-469B-A86F-91F0836EDD6AQ34341345-D32E6B58-DA2F-4D00-877D-5AC8475DCDDDQ34373275-FB450BAD-5DA0-4498-BFC5-8E4BAD70606CQ34447762-8237D7F3-C20C-43E0-9012-9D8F2A05C355Q34464743-D46A3332-12D3-4C78-9481-9DD87DBE034DQ34480617-0DD5A96E-10E6-4F66-AD38-5E562C907E62Q34540645-43A5BCB3-569C-4E85-B9E3-C16780C33247Q34540809-0E0678F0-90DE-43A3-8F77-7C8A7F6673A1Q34541191-6EC6A81D-7EC0-49F5-A290-DF895C770695Q34625042-627FFB79-3A50-4A74-AA19-5F2BF4E67475Q34658459-1CAA3171-4EAD-4A11-8A4E-8275514CC54FQ34816639-ABB4DFC1-40D0-4139-BF77-813D5B88ADEEQ35088691-DB5A79AA-E014-4B4B-BE4B-DA1A55B14EE5Q35160124-48008017-EBF6-4C2C-8369-A286342FA624Q35161553-63BE6CCC-1DEC-47D1-BE76-B72B150981C8Q35382338-72EE8D0E-98F2-48BE-B692-DD728F341507Q35484743-B9248FED-7B1D-4F82-9A3F-9FD93E23E2DAQ35666180-1A86FA82-600D-43B6-A274-CD6B90FD7851Q35774494-1F4F9DEC-5FEE-403C-A742-BF49C70AD0E2Q35980530-3B324F0F-97D7-4403-B669-B767D1FF300BQ36084253-A791E627-D958-4669-9A58-6E656BAAFE0CQ36276187-156A0030-9963-4A3C-8AFF-997EE414621A
P2860
Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@en
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@nl
type
label
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@en
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@nl
prefLabel
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@en
Adenovirus vector vaccination ...... readily susceptible to HIV-1.
@nl
P2093
P2860
P356
P1476
Adenovirus vector vaccination ...... e readily susceptible to HIV-1
@en
P2093
Adel Benlahrech
Andre Lieber
Andrea Meiser
Eszter Csomor
Frances Gotch
George Dickson
Julia Hornig
Julian Harris
Karen Logan
Kerry Fisher
P2860
P304
19940-19945
P356
10.1073/PNAS.0907898106
P407
P577
2009-11-16T00:00:00Z